BerGenBio Investor Relations Material
Latest events
Q4 2023
BerGenBio
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from BerGenBio
Access all reports
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. BerGenBio has also initiated its early stage development programs on epacadostat and devicine.
Key slides for BerGenBio
Latest articles
The Rise of Copart: From Salvage Yard to Tech Giant
Explore Copart's capital allocation mastery, its competitive advantages, and its transformation from a local salvage yard to a $53 billion empire.
18 Mar 2024
Companies That Had Their IPO in 1998: The Inflating Dot Com Bubble
An overview of the market sentiment and IPO landscape as the dot com bubble continued to inflate during the late 90s.
18 Mar 2024
The Coca-Cola and Pepsi Duopoly: The Secret Ingredients
Dive into the iconic rivalry between Coca-Cola and Pepsi, the two behemoths of the soft drink industry, and their primary competitive strengths.
15 Mar 2024
Ticker symbol
Country
🇳🇴 Norway